PSMB2

Proteasome Macropain subunit

43,187 patent compounds predicted against PSMB2, 29,219 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL605949	0.54	15/20
SCHEMBL607010	0.56	12/20
SCHEMBL607553	0.54	12/20
SCHEMBL606932	0.53	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL606926	0.52	12/20
SCHEMBL606344	0.51	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL607035	0.61	11/20
SCHEMBL605158	0.59	11/20
SCHEMBL606315	0.59	11/20
SCHEMBL85003	0.58	11/20
SCHEMBL85066	0.56	11/20
SCHEMBL464494	0.56	11/20
SCHEMBL464427	0.55	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL607962	0.54	11/20
SCHEMBL605822	0.54	11/20
SCHEMBL608362	0.53	11/20
SCHEMBL605129	0.52	11/20

Germline variants in PSMB2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PSMB2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PSMB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis	PHASE2	RECRUITING
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
A Prevention Trial in Subjects at High Risk for Breast Cancer	PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	PHASE2	COMPLETED
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas	PHASE2	COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer	PHASE1	COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma	PHASE1	COMPLETED
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery	PHASE1	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMB2 binder may also engage these)

Protein	Name	Similarity
Q5E9K0	—	1.000	Q5E9K0 →
P40307	—	1.000	P40307 →
Q9R1P3	—	1.000	Q9R1P3 →
O23714	—	0.987	O23714 →
Q9LST6	—	0.984	Q9LST6 →
O24633	—	0.984	O24633 →
Q9P6U7	—	0.981	Q9P6U7 →
P28024	—	0.979	P28024 →
Q3T108	—	0.975	Q3T108 →
P34067	—	0.973	P34067 →
P99026	—	0.971	P99026 →
PSMB1	Proteasome component C5	0.968	landscape →
PSMB4	Proteasome subunit beta type-4	0.967	landscape →
Q9IB83	—	0.966	Q9IB83 →
P18421	—	0.964	P18421 →
Q2TBX6	—	0.963	Q2TBX6 →
Q6DRF3	—	0.963	Q6DRF3 →
Q9IB84	—	0.963	Q9IB84 →
O09061	—	0.957	O09061 →
P22141	—	0.953	P22141 →
O48551	—	0.952	O48551 →
Q7DLR9	—	0.952	Q7DLR9 →
O81147	—	0.950	O81147 →
Q9XG77	—	0.949	Q9XG77 →
Q09720	—	0.948	Q09720 →
Q9UQY2	—	0.948	Q9UQY2 →
O81146	—	0.947	O81146 →
P23724	—	0.946	P23724 →
Q9LSU3	—	0.945	Q9LSU3 →
P40304	—	0.945	P40304 →